Would you switch to TDM-1 in the adjuvant setting in HER-2 positive breast cancer patients with residual disease after neoadjuvant chemotherapy if neoadjuvant chemotherapy did not include anthracyclines?
Only a small subset (22-24%) of patients in Katherine trial received a non-anthracycline containing regimen.
So far, insurance companies in my area are not app...